1.
Sarcoidosis Vasc Diffuse Lung Dis
; 31(3): 235-8, 2014 Oct 20.
Artículo
en Inglés
| MEDLINE
| ID: mdl-25363224
RESUMEN
Interstitial lung disease is the most common complication and cause of death among patients with scleroderma. Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest and long-term administration of this drug is associated with adverse effects. Herein, we report our clinical experience of administering pirfenidone, which is an antifibrotic agent, in five patients with scleroderma-related interstitial lung disease. All patients demonstrated an increase in vital capacity.